G0726L117

Organogenesis Holdings Inc.

Could not find a ticker for this position, may be a filing error

A regenerative medicine company that grows living skin and tissue products to help wounds heal. Its best-known product, Apligraf, is a living skin substitute used to treat diabetic foot ulcers and venous leg ulcers, while its PuraPly and Affinity lines provide antimicrobial and amniotic membrane dressings for surgeons and wound-care clinics. Founded in 1985 in Massachusetts, the company's name reflects its founding mission of growing organs and tissues in the lab rather than just making bandages.

Warrant to purchase one-half of one Class A ordinary share, expiring approximately October 7, 2026